glp 1 with blue cross blue shield to stop covering popular weight-loss drugs Blue Cross Blue Shield GLP-1

GLP-1 medications like Ozempic and Wegovy have surged in popularity as weight loss treatments, but ophthalmologists say their potential risks to eye health are not well understood

Pemvidutide (ALT-801) is another unimolecular once weekly GLP-1/glucagon agonist undergoing a phase 2 trial as obesity treatment, following a phase 1 trial demonstrating up to 10.3% WL at 12 weeks [73]

Either works

Phase 3 clinical trial results released in May 2026 showed participants lost up to 28.3% of their body weight over 80 weeks, making it potentially more effective than semaglutide (Ozempic and Wegovy) and tirzepatide (Zepbound and Mounjaro)

Type 2 diabetes data In a separate Phase 2 trial, retatrutide was tested in adults with type 2 diabetes

Factors influencing retatrutide dosing for weight loss Several factors may influence the optimal dosage for an individual, such as: Body weight and BMI : Individuals with higher body mass index may need retatrutide treatment for a longer time and at higher doses to achieve significant weight loss